Saturday 17 October 2026
Export CMPX’s income statement to Excel — free account
Compass Therapeutics, Inc.
CMPX Healthcare Biotechnology
Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00. In the quarter to June 2026, EPS grew 7.14% and free cash flow fell 26.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow CMPX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (56.66%) | (45.95%) | (41.29%) | (37.82%) |
+8 more TTM periods Free account |
|
| (47.87%) | (40.50%) | (36.94%) | (34.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(44.49%) | (36.74%) | (33.93%) | (31.51%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.30) | (0.29) | (0.31) | (0.27) | |
Free Cash Flow |
(56.37) | (53.29) | (49.17) | (45.08) | |
Capital Expenditures |
(0.26) | (0.09) | (0.02) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(16.30%) | (13.98%) | (12.12%) | (10.49%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.76 | 0.78 | 0.74 | 0.68 | |
Depreciation/Fixed assets |
(1.51) | (2.54) | (1.97) | 6.00 | |
Capex/Depreciation |
0.54 | 0.21 | 0.12 | (0.03) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.29) | (0.31) | (0.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates